, Volume 11, Issue 5, pp 799–812 | Cite as

Indole-3-carbinol-induced death in cancer cells involves EGFR downregulation and is exacerbated in a 3D environment

  • E. P. MoiseevaEmail author
  • L. H. Fox
  • L. M. Howells
  • L. A. F. Temple
  • M. M. Manson


Indole-3-carbinol (I3C) is a promising anticancer dietary compound, which inhibits breast cancer in animal models. The objective of the current study was to characterize I3C-induced cell death in a panel of human breast tumorigenic cells (MCF7, MDA-MB-468, MDA-MB-231 and HBL100) in comparison with normal fibroblasts. Since epithelial cells are protected from cell death by a three-dimensional environment, 3D cell culture (collagen I gel and spheroids) was employed to investigate susceptibility to I3C. Cell viability in the presence of 256 μM I3C, a concentration close to the physiologically achievable range, was in the order fibroblasts = HBL100>MDA-MB-231>MCF7>MDA-MB-468 in monolayer culture. However, 3D culture conditions increased the susceptibility of MCF7 and MDA-MB-468 cancer cells towards I3C. I3C induced cell death in breast cancer MCF7, MDA-MB-468 and MDA-MB–231 cells via the mitochondrial apoptotic pathway. I3C significantly reduced levels of epidermal growth factor receptor (EGFR) in MDA-MB-468 after 6 h and in MDA-MB-231 and HBL100 cells after 30 h. Downregulation of EGFR in MDA-MB468 and MDA-MB-231 cells using an EGFR inhibitor resulted in apoptosis. EGFR modulation using EGF or an EGFR inhibitor markedly influenced viability and response to I3C in MDA-MB-468 cells in 3D conditions. EGFR expression was modulated by 3D conditions. Therefore, I3C-induced EGFR reduction in these cells is likely to be responsible for I3C-induced apoptosis.


apoptosis breast cancer epidermal growth factor receptor indole-3-carbinol 3D cell culture 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parkin DM, Whelan SL, Storm H. Cancer incidence in five continents. Lyon: IARC 7; 2005.Google Scholar
  2. 2.
    Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197–1200.PubMedCrossRefGoogle Scholar
  3. 3.
    Linseisen J, Piller R, Hermann S, Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2004; 110: 284–290.PubMedCrossRefGoogle Scholar
  4. 4.
    IARC. Cruciferous vegetables, isothiocyanates and indoles. IARC Handbooks of Cancer Prevention. Lion: IARC Press 2004; 9: 1–262.Google Scholar
  5. 5.
    Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000; 78: 123–129.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004; 18: 248–253.PubMedCrossRefGoogle Scholar
  7. 7.
    Bradlow HL, Michnovicz J, Telang NT, Osborne MP. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 1991; 12: 1571–1574.PubMedGoogle Scholar
  8. 8.
    Kojima T, Tanaka T, Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 1994; 54: 1446–1449.PubMedGoogle Scholar
  9. 9.
    Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP. Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 1994; 86: 126–131.PubMedGoogle Scholar
  10. 10.
    Telang NT, Katdare M, Bradlow HL, Osborne MP, Fishman J. Inhibition of proliferation and modulation of estradiol metabolism: Novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med 1997; 216: 246–252.PubMedGoogle Scholar
  11. 11.
    Cover CM, Hsieh SJ, Tran SH, et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 1998; 273: 3838–3247.PubMedCrossRefGoogle Scholar
  12. 12.
    Ge X, Fares FA, Yannai S. Induction of apoptosis in MCF-7 cells by indole-3-carbinol is independent of p53 and Bax. Anticancer Res 1999; 19: 3199–3203.PubMedGoogle Scholar
  13. 13.
    Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther 2002; 1: 1161–1172.PubMedGoogle Scholar
  14. 14.
    Jeon KI, Rih JK, Kim HJ, et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 2003; 544: 246–251.PubMedCrossRefGoogle Scholar
  15. 15.
    Rahman KM, Aranha O, Glazyrin A, Chinni SR, Sarkar FH. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 2000; 19: 5764–5771.PubMedCrossRefGoogle Scholar
  16. 16.
    Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001; 20: 2927–2936.PubMedCrossRefGoogle Scholar
  17. 17.
    Chinni SR, Sarkar FH. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 2002; 8: 1228–1236.PubMedGoogle Scholar
  18. 18.
    Sarkar FH, Rahman KM, Li Y. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J Nutr 2003; 133: 2434S–2439S.PubMedGoogle Scholar
  19. 19.
    Ashok BT, Chen YG, Liu X, et al. Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev 2002; 11: S86–S93.PubMedGoogle Scholar
  20. 20.
    Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles ‘heal' of lung cancers? Trends Mol Med 2004; 10: 481–486.PubMedCrossRefGoogle Scholar
  21. 21.
    Laskin JJ, Sandler AB. Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treat Rev 2004; 30: 1–17.PubMedCrossRefGoogle Scholar
  22. 22.
    Weaver VM, Petersen OW, Wang F, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137: 231–245.PubMedCrossRefGoogle Scholar
  23. 23.
    Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 2002; 115: 39–50.PubMedGoogle Scholar
  24. 24.
    Weaver VM, Lelievre S, Lakins JN, et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002; 2: 205–216.PubMedCrossRefGoogle Scholar
  25. 25.
    Durand RE, Olive PL. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol 2001; 64: 211–233.PubMedCrossRefGoogle Scholar
  26. 26.
    dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis 2002; 19: 161–168.CrossRefGoogle Scholar
  27. 27.
    Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001; 10: 243–248.PubMedGoogle Scholar
  28. 28.
    Jensen BV, Johansen JS, Skovsgaard T, Brandt J, Teisner B. Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer 2002; 98: 582–589.PubMedCrossRefGoogle Scholar
  29. 29.
    Wang W, Wyckoff JB, Frohlich VC, et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 2002; 62: 6278–6288.PubMedGoogle Scholar
  30. 30.
    Tanino H, Oura S, Hoffman RM, et al. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 2001; 21: 4083–4086.PubMedGoogle Scholar
  31. 31.
    Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H, Noguchi S. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 2002; 98: 450–455.PubMedCrossRefGoogle Scholar
  32. 32.
    Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int J Cancer 2003; 106: 8–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 1998; 21: 261–272.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11: 204–215.PubMedGoogle Scholar
  35. 35.
    Gaffney EV. A cell line (HBL-100) established from human breast milk. Cell Tissue Res 1982; 227: 563–568.PubMedCrossRefGoogle Scholar
  36. 36.
    Caron de Fromentel C, Nardeux PC, Soussi T, et al. Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. Exp Cell Res 1985; 160: 83–94.CrossRefGoogle Scholar
  37. 37.
    Gottlieb E, Vander Heiden MG, Thompson CB. Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 2000; 20: 5680–5689.PubMedCrossRefGoogle Scholar
  38. 38.
    Sambrook J, Russell DW. Molecular Cloning, 3rd edition. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 2001.Google Scholar
  39. 39.
    Anderton MJ, Manson MM, Verschoyle RD, et al. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 2004; 10: 5233–5241.PubMedCrossRefGoogle Scholar
  40. 40.
    Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357–9360.PubMedCrossRefGoogle Scholar
  41. 41.
    Martin SJ, Finucane DM, Amarante-Mendes GP, O'Brien GA, Green DR. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J Biol Chem 1996; 271: 28753–28756.PubMedCrossRefGoogle Scholar
  42. 42.
    Fitzpatrick SL, LaChance MP, Schultz GS. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res 1984; 44: 3442–3447.PubMedGoogle Scholar
  43. 43.
    Ennis BW, Valverius EM, Bates SE, et al. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 1989; 3: 1830–1838.PubMedCrossRefGoogle Scholar
  44. 44.
    Armstrong DK, Kaufmann SH, Ottaviano YL, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994; 54: 5280–5283.PubMedGoogle Scholar
  45. 45.
    Ramachandran C, You W. Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res Treat 1999; 54: 269–278.PubMedCrossRefGoogle Scholar
  46. 46.
    Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000; 376: 338–346.PubMedCrossRefGoogle Scholar
  47. 47.
    Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001; 98: 1853–1858.PubMedCrossRefGoogle Scholar
  48. 48.
    Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s–870s.PubMedGoogle Scholar
  49. 49.
    Moro L, Dolce L, Cabodi S, et al. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 2002; 277: 9405–9414.PubMedCrossRefGoogle Scholar
  50. 50.
    Bill HM, Knudsen B, Moores SL, et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol 2004; 24: 8586–8599.PubMedCrossRefGoogle Scholar
  51. 51.
    Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D, Lichtner RB. Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int J Cancer 1998; 75: 205–209.PubMedCrossRefGoogle Scholar
  52. 52.
    Hazan RB, Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998; 273: 9078–9084.PubMedCrossRefGoogle Scholar
  53. 53.
    Dangles V, Femenia F, Laine V, et al. Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines. Cancer Res 1997; 57: 3360–3364.PubMedGoogle Scholar
  54. 54.
    Mansbridge JN, Ausserer WA, Knapp MA, Sutherland RM. Adaptation of EGF receptor signal transduction to three-dimensional culture conditions: changes in surface receptor expression and protein tyrosine phosphorylation. J Cell Physiol 1994; 161: 374–382.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • E. P. Moiseeva
    • 1
    Email author
  • L. H. Fox
    • 1
  • L. M. Howells
    • 1
  • L. A. F. Temple
    • 1
  • M. M. Manson
    • 1
  1. 1.Cancer Biomarkers and Prevention Group, Departments of Biochemistry and Cancer StudiesUniversity of LeicesterLeicesterUK

Personalised recommendations